Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.

Mulet N, Matos I, Noguerido A, Martini G, Élez ME, Argilés G, Tabernero J.

Expert Opin Pharmacother. 2018 Apr;19(6):623-629. doi: 10.1080/14656566.2018.1453497. Epub 2018 Mar 28.

PMID:
29537896
2.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

PMID:
28626084
3.

Current and advancing treatments for metastatic colorectal cancer.

Sanz-Garcia E, Grasselli J, Argiles G, Elez ME, Tabernero J.

Expert Opin Biol Ther. 2016;16(1):93-110. doi: 10.1517/14712598.2016.1108405. Epub 2015 Nov 7. Review.

PMID:
26549053
4.

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.

Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J.

Clin Cancer Res. 2014 May 15;20(10):2793-804. doi: 10.1158/1078-0432.CCR-13-1837. Epub 2014 Mar 14.

5.

First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.

Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ.

Clin Cancer Res. 2014 Apr 15;20(8):2205-14. doi: 10.1158/1078-0432.CCR-13-1880. Epub 2014 Feb 21.

6.

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J.

PLoS One. 2013 Nov 11;8(11):e62264. doi: 10.1371/journal.pone.0062264. eCollection 2013.

7.

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.

Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG.

Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29.

8.

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis.

Bouchahda M, Macarulla T, Liedo G, Lévi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R.

Med Oncol. 2011 Dec;28 Suppl 1:S253-8. doi: 10.1007/s12032-010-9716-8. Epub 2010 Nov 5.

PMID:
21053102
9.

New approaches and targets in advanced colorectal cancer.

Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J.

Eur J Cancer. 2009 Sep;45 Suppl 1:79-88. doi: 10.1016/S0959-8049(09)70019-X. No abstract available.

PMID:
19775607

Supplemental Content

Support Center